The challenge of an increasingly expensive blood system

CMAJ. Canadian Medical Association Journal

Volumn 168, Issue 9, 2003, Pages 1149-1150

  Wilson, Kumanan ^a,b,d   Hébert, Paul C ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

BLOOD DONOR; BLOOD TRANSFUSION; CANADA; COST EFFECTIVENESS ANALYSIS; CREUTZFELDT JAKOB DISEASE; DISEASE TRANSMISSION; HEALTH CARE COST; HEALTH SERVICE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOTE; RED CROSS; SAFETY;

EID: 0038414864     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (18)

1. Krever H. Commission of inquiry on the blood system in Canada. Final report. Ottawa: Canadian Government Publishing; 1997.
2. Canadian Institute for Health Information. Health Spending to top $112 billion in 2002, reports Canadian Institute for Health Information. Part 2. Available: secure.cihi.ca/cihiweb/dispPage.jsp?cw_page=media_18dec2002_2_e#c harts (accessed 2003 Feb 18).
3. Health Canada. United Kingdom, France & Western Europe. Donor exclusion to address theoretical risk of transmission of variant Creutzfeldt-Jakob disease (vCJD) through the blood supply. Ottawa: Biologics and Genetic Therapies Directorate, Blood and Tissues Division, Health Canada; 2001 Aug. Available: www.hcsc.gc.ca/english/media/releases/2001/2001_96ebk1.htm (accessed 2003 Mar 31).
4. Council of Europe Expert Committee in Blood Transfusion Study Group on Pathogen Inactivation of Labile Blood Components. Pathogen inactivation of labile blood products. Transfus Med 2001;11:149-75.
5. Aubuchon JP, Petz LD. Making decisions to improve transfusion safety. In: AuBuchon JP, Petz LD, Fink A, editors. Policy alternatives in transfusion medicine. Bethesda (MD): AABB Press; 2001. p. 193-226.
6. Goodnough LT. The case against universal WBC reduction (and for the practice of evidence-based medicine). Transfusion 2000;40:1522-7.
7. Van Hulst M, de Wolf JT, Staginnus U, Ruitenberg EJ, Postma MJ. Pharmaco-economics of blood transfusion safety: a review of the available evidence. Vox Sang 2002;83:146-55.
8. Medical Payment Advisory Commission (MedPAC). Appendix A: safety regulation, standards and technology. In: Report to the Congress: blood safety in hospitals and Medicare inpatient payment. Washington: MedPAC; 2001. p. 17-26. Available: www.medpac.gov/publications/congressional_reports/dec2001BloodSaf ety.pdf (accessed 2003 Feb 18).
9. Pereira A, Sanz C. A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols. Transfusion 2000;40:1182-91.
10. Stramer SL. US NAT yield: Where are we after 2 years? Transfus Med 2002;12:243-53.
11. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-81.
12. Wilson K, Hebert P, Laupacis A, Dornan C, Ricketts M, Ahmad N, et al. A policy analysis of major decisions related to Creutzfeldt-Jakob disease and the blood supply. CMAJ 2001;165(1):59-65.
13. Wadsworth L. Focus: IVIG. Blood Matters 2002;4(1):2. Available: www.bloodlink.bc.ca/newsletter/bm-jan02.html (last updated 2002 June 16) (accessed 2003 Feb 18).
14. Pi D, Petraszko T. IVIG supply and cost. In: IVIG utilization management handbook. 1st ed. Vancouver (BC): Provincial Blood Coordinating Office; 2002. p. 1-3.
15. Canadian Blood Services National Liaison Committee (NLC). Report on April 2002 meeting. 2002 Apr 15; Ottawa. Available: www.transfusion.ca/downloads/CBS-NLC-April-2002.doc (accessed 2002 Mar 31).
16. Sher G. Situation in Canada. Plasma self-sufficiency in Canada - is it a matter of safety? National Blood Safety Council Open Forum; 2001 Mar 29-30; Vancouver. Available: www.bloodsafety.gc.ca/docs/2001/min/03/min_2001032930-dl-3-e.html (accessed 2003 Mar 31).
17. Hebert PC, Fergusson DA. Red blood cell transfusions in critically ill patients. JAMA 2002;288:1525-6.
18. Wilson K, MacDougall L, Fergusson D, Graham I, Tinmouth A, Hebert P. The effectiveness of interventions to reduce physician's levels of inappropriate transfusion: what can be learned from a systematic review of the literature. Transfusion 2002;42:1224-8.